Skip Navigation



Carcinogenesis Advance Access published online on April 18, 2006
Carcinogenesis, doi:10.1093/carcin/bgl043
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
27/10/2018    most recent
bgl043v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mantena, S. K.
Right arrow Articles by Katiyar, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mantena, S. K.
Right arrow Articles by Katiyar, S. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
Received January 26, 2006
Revised March 23, 2006
Accepted March 27, 2006

MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION

Berberine inhibits growth, induces G1 arrest and apoptosis in human epidermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin cascade, disruption of mitochondrial membrane potential and cleavage of caspase-3 and PARP

Sudheer K. Mantena 1, Som D. Sharma 1, and Santosh K. Katiyar 2 *

1 Department of Dermatology, University of Alabama at Birmingham, AL 35294
2 Department of Dermatology, University of Alabama at Birmingham, AL 35294; Skin Diseases Research Center, University of Alabama at Birmingham, AL 35294; Birmingham VA Medical Center, Birmingham, AL 35294, USA

* To whom correspondence should be addressed.
Santosh K. Katiyar, E-mail: skatiyar{at}uab.edu


  Abstract

Chemotherapeutic approach using non-toxic botanicals may be one of the strategies for the management of the skin cancers. Here we report that in vitro treatment of human epidermoid carcinoma A431 cells with berberine, a naturally occurring isoquinoline alkaloid, decreased cell viability (3-77%, p<0.05-0.001) and induced cell death (3-51%, p<0.01-0.001) in a dose (5-75 µM)- and time (12-72 h)-dependent manner, which was associated with an increase in G1 arrest. G0/G1 phase of the cell cycle is known to be controlled by cyclin dependent kinases (Cdk), cyclin kinase inhibitors (Cdki) and cyclins. Our western blot analysis showed that berberine-induced G1 cell cycle arrest was mediated through the increased expression of Cdki proteins (Cip1/p21 and Kip1/p27), a simultaneous decrease in Cdk2, Cdk4, Cdk6 and cyclins D1, D2 and E and enhanced binding of Cdki-Cdk. In additional studies, treatment of A431 cells with berberine (15-75 µM) for 72 h resulted in a significant dose-dependent increase in apoptosis (31-60%, p<0.05-0.001) than non-berberine-treated control (11.7%), which was associated with an increased expression of pro-apoptotic protein Bax, decreased expression of anti-apoptotic proteins Bcl-2 and Bcl-xl, disruption of mitochondrial membrane potential, and activation of caspase-9, caspase-3 and poly (ADP-ribose) polymerase. Pretreatment of A431 cells with the pan-caspase inhibitor (z-VAD-fmk) significantly blocked the berberine-induced apoptosis in A431 cells confirmed that berberine-induced apoptosis is mediated through activation of caspase-3-dependent pathway. Together, this study for the first time identified berberine as a chemotherapeutic agent against human epidermoid carcinoma A431 cells in vitro, further in vivo studies are required to determine whether berberine could be an effective chemotherapeutic agent for the management of nonmelanoma skin cancers.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anticancer ResHome page
Y.-T. HO, C.-C. LU, J.-S. YANG, J.-H. CHIANG, T.-C. LI, S.-W. IP, T.-C. HSIA, C.-L. LIAO, J.-G. LIN, W. G. WOOD, et al.
Berberine Induced Apoptosis via Promoting the Expression of Caspase-8, -9 and -3, Apoptosis-inducing Factor and Endonuclease G in SCC-4 Human Tongue Squamous Carcinoma Cancer Cells
Anticancer Res, October 1, 2009; 29(10): 4063 - 4070.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C.-H. Yoon, E.-S. Lee, D.-S. Lim, and Y.-S. Bae
PKR, a p53 target gene, plays a crucial role in the tumor-suppressor function of p53
PNAS, May 12, 2009; 106(19): 7852 - 7857.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Akhtar, S. M. Meeran, N. Katiyar, and S. K. Katiyar
Grape Seed Proanthocyanidins Inhibit the Growth of Human Non-Small Cell Lung Cancer Xenografts by Targeting Insulin-Like Growth Factor Binding Protein-3, Tumor Cell Proliferation, and Angiogenic Factors
Clin. Cancer Res., February 1, 2009; 15(3): 821 - 831.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
X. Mao, S.-b. Liang, R. Hurren, M. Gronda, S. Chow, G. W. Xu, X. Wang, R. B. Zavareh, N. Jamal, H. Messner, et al.
Cyproheptadine displays preclinical activity in myeloma and leukemia
Blood, August 1, 2008; 112(3): 760 - 769.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. K. Pandey, B. Sung, A. B. Kunnumakkara, G. Sethi, M. M. Chaturvedi, and B. B. Aggarwal
Berberine Modifies Cysteine 179 of I{kappa}B{alpha} Kinase, Suppresses Nuclear Factor-{kappa}B-Regulated Antiapoptotic Gene Products, and Potentiates Apoptosis
Cancer Res., July 1, 2008; 68(13): 5370 - 5379.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. C. Pereira, A. F. Branco, J. A. C. Matos, S. L. Pereira, D. Parke, E. L. Perkins, T. L. Serafim, V. A. Sardao, M. S. Santos, A. J. M. Moreno, et al.
Mitochondrially Targeted Effects of Berberine [Natural Yellow 18, 5,6-dihydro-9,10-dimethoxybenzo(g)-1,3-benzodioxolo(5,6-a) quinolizinium] on K1735-M2 Mouse Melanoma Cells: Comparison with Direct Effects on Isolated Mitochondrial Fractions
J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 636 - 649.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.